Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAM-MS: autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine, or ocrelizumab in relapsing-remitting multiple sclerosis
2024-510630-40-00Phase 3Authorised
- Sponsor
- Helse Bergen
- Start
- Feb 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised trial of cyclophosphamide, alemtuzumab, cladribine, ocrelizumab and antithymocyte immunoglobulin in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Helse Bergen. Primary endpoint: No evidence of disease activity at 2 years and 5 years. Planned start Feb 2018; status: authorised.
02
Drugs
cyclophosphamidealemtuzumabcladribineocrelizumabantithymocyte immunoglobulin
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2024-510630-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510630-40-00.